ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2026
Episodic Heavy Drinking and Implications for Steatotic Liver Disease Nomenclature: A National Cross-Sectional Study.
Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
BACKGROUND &
aimsFederal agencies define heavy drinking by average increased or episodic heavy alcohol consumption, yet steatotic liver disease (SLD) nomenclature only captures average alcohol consumption to define subcategories. We evaluated episodic heavy drinking among SLD subcategories and its association with liver fibrosis.
methodsWe utilized the 2017 to 2023 National Health and Nutrition Examination Survey (NHANES) including adults with vibration-controlled transient elastography data. Significant and advanced liver fibrosis were liver stiffness ≥8 and ≥12 kPa. Episodic heavy drinking was ≥4 drinks (women) and ≥5 (men) on any day, at least once per month. Multivariable logistic regression (adjusted for age, sex, average alcohol consumption) analyzed the association of episodic heavy drinking with liver fibrosis in SLD groups.
resultsAmong 8006 individuals, 4571 had SLD: 3969 had metabolic dysfunction-associated steatotic liver disease (MASLD), 373 had metabolic and alcohol-associated liver disease (MetALD), and 144 had alcohol-associated liver disease (ALD). Among patients with MASLD, 632 (15.9%) had episodic heavy drinking, which was associated with significant (adjusted odds ratio, 1.69; 95% confidence interval [CI], 1.11-2.58) and advanced (adjusted odds ratio, 2.76; 95% CI, 1.58-4.80) liver fibrosis. Adjusted weighted-prevalence of significant liver fibrosis among MASLD with episodic heavy drinking (23.6%; 95% CI, 17.6%-29.6%) was higher than MASLD without episodic heavy drinking (15.6%; 95% CI, 13.5%-17.6%]). Subgroup prevalence using consensus nomenclature vs including episodic heavy drinking as MetALD or ALD decreased the weighted prevalence of MASLD (48.0%; 95% CI, 46.0%-50.0% to 40.4%; 95% CI, 38.5%-42.4%), increased MetALD (5.3%; 95% CI, 4.6%-6.1% to 12.9%; 95% CI, 11.9%-13.9%), whereas ALD was similar (1.9%; 95% CI, 1.5%-2.3% to 2.1%; 95% CI, 1.7%-2.5%).
conclusionsEpisodic heavy drinking is prevalent in MASLD and associated with 3-fold higher odds of advanced liver fibrosis. Reclassifying these patients to MetALD would more than double the estimated prevalence of MetALD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.